Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy

Trial Profile

A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Dong-A ST
  • Most Recent Events

    • 13 Dec 2018 Planned End Date changed from 31 Oct 2018 to 31 Aug 2019.
    • 13 Dec 2018 Planned primary completion date changed from 31 Aug 2018 to 31 Dec 2018.
    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top